BioGaia Signs Two New Distribution Agreements and Yet Another Study on Periodontitis Shows Positive Results

Published: Dec 17, 2012

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: BioGaia (STO:BIOG) has today signed two different agreements for its oral health products, one with Pharmaforte for the Singapore Republic, and one with Dexcel Pharma, for Israel. Recently a double-blind, placebo-controlled, randomised study in twenty patients with periodontitis was published. The results showed that pocket depth, the most important disease indicator, was significantly reduced in the patients supplemented by the probiotic Lactobacillus reuteri Prodentis compared to the placebo group. Both agreements are exclusive and refer to the sales of BioGaia’s oral health products. In both countries the products will be sold under the BioGaia brand and launches are planned to take place during 2013. BioGaia’s oral health products contain the patented and well-studied probiotic Lactobacillus reuteri Prodentis. Today BioGaia's oral health products are sold in more than 20 countries worldwide.

Back to news